The world’s first long-acting anti-RSV monoclonal antibody has been commercially launched
October 20, 2026
Source: drugdu
28
Recently, the domestically developed long-acting anti-respiratory syncytial virus (RSV) monoclonal antibody, ritvirabimab injection (trade name: Newdox), was launched in Jinwan District, Zhuhai. This is the world's first long-acting anti-RSV monoclonal antibody with 9 months of protection data after a single injection, and it was independently developed and produced by Zhuhai TechnoMed Pharmaceutical Co., Ltd.
RSV is one of the most common pathogens causing lower respiratory tract infections in infants and young children. The risk of infection increases significantly during the autumn and winter seasons. It is often associated with diseases such as severe pneumonia and bronchiolitis, and poses a particularly prominent threat to premature infants, low birth weight infants, and infants with congenital cardiopulmonary diseases.
Source: https://mp.weixin.qq.com/s?__biz=MzIxMjYwMDI5Nw==&mid=2247717580&idx=3&sn=3f2a07c30d243e6b52fc0aeb2869baee&chksm=96e51b57c73949dc987f0a25e6a5421a12bfd06db7332796d4078d21b0d18e20c36f3d42b430&scene=126&sessionid=0#rd
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- FDA Approves Revolution Medicines’ Oral RAS Inhibitor Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer October 20, 2026
- Hansoh Pharma Enters Strategic ADC Collaboration with Roche Worth Over US$15.5 Billion October 20, 2026
- New cough medicine launched October 20, 2026
- Shining on the top stage! The world’s first three-target agonist DR10624 MASLD/MASH Phase II results were selected for the latest breakthrough abstract of AASLD. October 20, 2026
- Lunan Pharmaceutical’s Weikangda® Tegafur Capsules Receive Marketing Approval in Pakistan October 20, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
